A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
A phase 1/2 trial of 3HP-2827 in advanced solid tumours, run by 3H (Suzhou) Pharmaceuticals Co., Ltd., now recruiting.
Overview
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations is a phase 1/2 interventional study registered as NCT06378593 by 3H (Suzhou) Pharmaceuticals Co., Ltd., with 130 participants planned, started 2024-06-17 and due to reach its primary completion in 2028-06-16. Interventions recorded: 3HP-2827.
Similar pages
not linked directly; found by shared links- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.